700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Novavax, Inc. Enters Material Agreement with AstraZeneca for Facility Lease
Continues to Deliver on Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
News, Securities Holder Rights or Indentures
Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Announces Convertible Debt Refinancing
Reports Second Quarter 2025 Financial Results and Operational Highlights
Shareholder votes
46 th Annual Global Healthcare Conference June 11, 2025
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Free Writing Prospectus
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload
Confidential Treatment Order